The Pigeonhole of Occult Hepatitis B

  • Payam Dindoost Department of Gastroenterology, Middle East Liver Diseases Center (MELD Centers), Tehran, Iran.
  • Narges Chimeh Department of Psychiatry, Family Research Institute, Shahid Beheshti University, Tehran, Iran.
  • Blain F Hollinger Department of Gastroenterology, Baylor College of Medicine One Baylor Plaza, Houston, USA.
  • Esmaeil Saberfar Department of Virology, Bayerpaul (BP) Vaccines and Pharmaceutical Company, Tehran, Iran.
  • Mehdi Norouzi Department of Virology, Faculty of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
  • Seyed Mohammad Jazayeri Mail Department of Virology, Faculty of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Keywords:
Occult Hepatitis B infection, HBV diagnosis, HBsAg mutations

Abstract

Occult hepatitis B (OHB), or persistent hepatitis B virus (HBV) viremia in surface-antigen-HBsAg-negative patients, has been recognized as a medical concern during the last decade. The exact magnitude, pathogenesis and clinical relevance of OHB are unclear. This review organizes the published data on OHB and presents an overview of the current hypotheses on OHB's pathogenesis and clinical relevance.Many explanations have been offered for the pathogenesis of OHB, ranging from the inability of standard immunoassays to diagnose OHB to the involvement of the versatile virus-host factors. Also, special care should be taken regarding the diagnosis of OBH. It seems that both shared viral-host factors are involved in the pathogenesis of OBH. Further molecular studies on cohort patients group need to explore such association.

References

Chaudhuri V, Tayal R, Nayak B, et al. Occult hepatitis B virus infection in chronic liver disease: full-length genome and analysis of mutant surface promoter. Gastroenterology 2004;127(5):1356-71.

Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002;9(4):243-57.

Kreutz C. Molecular, immunological and clinical properties of mutated hepatitis B viruses. J Cell Mol Med 2002;6(1):113-43.

Mosley JW, Stevens CE, Aach RD, et al. Donor screening for antibody to hepatitis B core antigen and hepatitis B virus infection in transfusion recipients. Transfusion 1995;35(1):5-12.

Coffin CS, Pham TN, Mulrooney PM, et al. Persistence of isolated antibodies to woodchuck hepatitis virus core antigen is indicative of occult infection. Hepatology 2004;40(5):1053-61.

Michalak TI, Mulrooney PM, Coffin CS. Low doses of hepadnavirus induce infection of the lymphatic system that does not engage the liver. J Virol 2004;78(4):1730-8.

Lew YY, Michalak TI. In vitro and in vivo infectivity and pathogenicity of the lymphoid cell-derived woodchuck hepatitis virus. J Virol 2001;75(4):1770-82.

Brechot C, Thiers V, Kremsdorf D, et al. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology 2001;34(1):194-203.

Zerbini A, Pilli M, Boni C, et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 2008;134(5):1470-81.

Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 1997;4(Suppl 1):11-20.

Tamori A, Nishiguchi S, Kubo S, et al. Sequencing of human-viral DNA junctions in hepatocellular carcinoma from patients with HCV and occult HBV infection. J Med Virol 2003;69(4):475-81.

Murakami Y, Minami M, Daimon Y, et al. Hepatitis B virus DNA in liver, serum, and peripheral blood mononuclear cells after the clearance of serum hepatitis B virus surface antigen. J Med Virol 2004;72(2):203-14.

Ackerman Z, Wands JR, Gazitt Y, et al. Enhancement of HBsAg detection in serum of patients with chronic liver disease following removal of circulating immune complexes. J Hepatol 1994;20(3):398-404.

Yotsuyanagi H, Yasuda K, Moriya K, et al. Frequent presence of HBV in the sera of HBsAg-negative, anti-HBcpositive blood donors. Transfusion 2001;41(9):1093-9.

Cacciola I, Pollicino T, Squadrito G, et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999;341(1):22-6.

De Maria N, Colantoni A, Friedlander L, et al. The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol 2000;95(12):3529-36.

Giannini E, Ceppa P, Botta F, et al. Previous hepatitis B virus infection is associated with worse disease stage and occult hepatitis B virus infection has low prevalence and pathogenicity in hepatitis C virus-positive patients. Liver Int 2003;23(1):12-8.

Rodriguez-Inigo E, Mariscal L, Bartolome J, et al. Distribution of hepatitis B virus in the liver of chronic hepatitis C patients with occult hepatitis B virus infection. J Med Virol 2003;70(4):571-80.

Filippini P, Coppola N, Pisapia R, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS 2006;20(9):1253-60.

Lo Re V 3rd, Frank I, Gross R, et al. Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr 2007;44(3):315-20.

Lukhwareni A, Burnett RJ, Selabe SG, et al. Increased detection of HBV DNA in HBsAg-positive and HBsAgnegative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital. J Med Virol 2009;81(3):406-12.

Mphahlele MJ, Lukhwareni A, Burnett RJ, et al. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol 2006;35(1):14-20.

Carman WF, Zanetti AR, Karayiannis P, et al. Vaccineinduced escape mutant of hepatitis B virus. Lancet 1990;336(8711):325-9.

Chen BF, Chen PJ, Jow GM, et al. High prevalence of mixed genotype infections in hepatitis B virus infected intravenous drug users. J Med Virol 2004;74(4):536-42.

Chen BF, Kao JH, Liu CJ, et al. Genotypic dominance and novel recombinations in HBV genotype B and C coinfected intravenous drug users. J Med Virol 2004;73(1):13-22.

Okamoto H, Omi S, Wang Y, et al. The loss of subtypic determinants in alleles, d/y or w/r, on hepatitis B surface antigen. Mol Immunol 1989;26(2):197-205.

Wallace LA, Echevarria JE, Echevarria JM, et al. Molecular characterization of envelope antigenic variants of hepatitis B virus from Spain. J Infect Dis 1994;170(5):1300-3.

Mangold CM, Unckell F, Werr M, et al. Secretion and antigenicity of hepatitis B virus small envelope proteins lacking cysteines in the major antigenic region. Virology 1995;211(2):535-43.

Pollicino T, Belloni L, Raffa G, et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 2006;130(32):823-37.

Sheldon J, Rodes B, Zoulim F, et al. Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat 2006;13(7):427-34.

Vivekanandan P, Kannangai R, Ray SC, et al. Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples. Clin Infect Dis 2008;46(8):1227-36.

Fang Y, Teng X, Xu WZ, et al. Molecular characterization and functional analysis of occult hepatitis B virus infection in Chinese patients infected with genotype C. J Med Virol 2009;81(5):826-35.

van Hemert FJ, Zaaijer HL, Berkhout B, et al. Occult hepatitis B infection: an evolutionary scenario. Virol J 2008;5(12):146-58.

Cabrerizo M, Bartolome J, Caramelo C, et al. Molecular analysis of hepatitis B virus DNA in serum and peripheral blood mononuclear cells from hepatitis B surface antigennegative cases. Hepatology 2000;32(1):116-23.

Blum HE, Galun E, Liang TJ, et al. Naturally occurring missense mutation in the polymerase gene terminating hepatitis B virus replication. J Virol 1991;65(4):1836-42.

Gujar SA, Michalak TI. Primary occult hepadnavirus= infection induces virus-specific T-cell and aberrant cytokine responses in the absence of antiviral antibody reactivity in the Woodchuck model of hepatitis B virus minfection. J Virol 2009;83(8):3861-76.

Hassanshahi G, Arababadi MK, Khoramdelazad H, et al. Assessment of CXCL12 (SDF-1alpha) polymorphisms and its serum level in posttransfusion occult HBV-infected patients in Southeastern Iran. Arch Med Res 2010;41(5):338-42.

Bhargava A, Khan S, Panwar H, et al. Occult hepatitis B virus infection with low viremia induces DNA damage, apoptosis and oxidative stress in peripheral blood lymphocytes. Virus Res 2010;153(1):143-50.

Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13(1):29-60.

Chemin I, Trepo C. Clinical impact of occult HBV infections. J Clin Virol 2005;34(Suppl 1):S15-21.

Pollicino T, Raffa G, Costantino L, et al. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology 2007;45(2):277-85.

Shahmoradi S, Yahyapour Y, Mahmoodi M, et al. High prevalence of occult hepatitis B virus infection in children born to HBsAg-positive mothers despite prophylaxis with hepatitis B vaccination and HBIG. J Hepatol 2012;57(3):515-21.

Raimondo G, Pollicino T, Cacciola I, et al. Occult hepatitis B virus infection. J Hepatol 2007;46(1):160-70.

Minuk GY, Sun DF, Greenberg R, et al. Occult hepatitis B irus infection in a North American adult hemodialysis patient population. Hepatology 2004;40(5):1072-7.

Minuk GY, Sun DF, Uhanova J, et al. Occult hepatitis B virus infection in a North American community-based population. J Hepatol 2005;42(4):480-5.

Kim SM, Lee KS, Park CJ, et al. Prevalence of occult HBV infection among subjects with normal serum ALT levels in Korea. J Infect 2007;54(2):185-91.

Firnhaber C, Viana R, Reyneke A, et al. Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa. Int J Infect Dis 2009;13(4):488-92.

Mphahlele MJ, Moloto MJ. Detection of HBV DNA from serologically negative or 'silent' HBV infections--viral or host factors? S Afr Med J 2002;92(8):613-5.

Sagnelli E, Imparato M, Coppola N, et al. Diagnosis and clinical impact of occult hepatitis B infection in patients with biopsy proven chronic hepatitis C: a multicenter study. J Med Virol 2008;80(9):1547-53.

Mrani S, Chemin I, Menouar K, et al. Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C. J Med Virol 2007;79(8):1075-81.

Stratta P, Bruschetta E, Minisini R, et al. Prevalence and clinical relevance of occult hepatitis B virus infection in patients on the waiting list for kidney transplantation. Transplant Proc 2009;41(4):1132-7.

Manzini P, Girotto M, Borsotti R, et al. Italian blood donors with anti-HBc and occult hepatitis B virus infection. Haematologica 2007;92(12):1664-70.

Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49(4):652-7.

Knoll A, Hartmann A, Hamoshi H, et al. Serological pattern "anti-HBc alone": characterization of 552 individuals and clinical significance. World J Gastroenterol 2006;12(8):1255-60.

Fang ZL, Zhuang H, Wang XY, et al. Hepatitis B virusmgenotypes, phylogeny and occult infection in a region with a high incidence of hepatocellular carcinoma in China. World J Gastroenterol 2004;10(22):3264-8.

Grob P, Jilg W, Bornhak H, et al. Serological pattern "anti- HBc alone": report on a workshop. J Med Virol 2000;62(4):450-5.

Wagner AA, Denis F, Weinbreck P, et al. Serological pattern 'anti-hepatitis B core alone' in HIV or hepatitis C virus-infected patients is not fully explained by hepatitis B surface antigen mutants. AIDS 2004;18(3):569-71.

Alavian SM, Miri SM, Hollinger FB, et al. Occult Hepatitis B (OBH) in Clinical Settings. Hepat Mon 2012;12(8):e6126.

Cacciola I, Pollicino T, Squadrito G, et al. Quantification of intrahepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection. Hepatology 2000;31(2):507-12.

Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100(1):182-8.

Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002;2(8):479-86.

Chemin I, Jeantet D, Kay A, et al. Role of silent hepatitis B virus in chronic hepatitis B surface antigen(-) liver disease. Antiviral Res 2001;52(2):117-23.

Donato F, Gelatti U, Limina RM, et al. Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence. Oncogene 2006;25(27):3756-70.

Sagnelli E, Coppola N, Scolastico C, et al. HCV genotype and "silent" HBV coinfection: two main risk factors for a more severe liver disease. J Med Virol 2001;64(3):350-5.

Marusawa H, Uemoto S, Hijikata M, et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 2000;31(2):488-95.

Shih LN, Sheu JC, Wang JT, et al. Serum hepatitis B virus DNA in healthy HBsAg-negative Chinese adults evaluated by polymerase chain reaction. J Med Virol 1990;32(4):257-60.

Fukuda R, Ishimura N, Niigaki M, et al. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol 1999;58(3):201-7.

Hui CK, Lau E, Monto A, et al. Natural history of patients with recurrent chronic hepatitis C virus and occult hepatitis B co-infection after liver transplantation. Am J Transplant 2006;6(7):1600-8.

Peres AA, Dias EA, Chesky M, et al. Occult hepatitis B in renal transplant patients. Transpl Infect Dis 2005;7(2):51-6.

Shetty K, Hussain M, Nei L, et al. Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl 2008;14(4):534-40.

Chazouilleres O, Mamish D, Kim M, et al. "Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994;343(8890):142-6.

Marrero JA, Lok AS. Occult hepatitis B virus infection in patients with hepatocellular carcinoma: Innocent bystander, cofactor, or culprit? Gastroenterology 2004;126(1):347-50.

Raimondo G. Occult hepatitis B virus infection and liver disease: fact or fiction? J Hepatol 2001;34(3):471-3.

Uemoto S, Sugiyama K, Marusawa H, et al. Transmissionof hepatitis B virus from hepatitis B core antibody-positivedonors in living related liver transplants. Transplantation 1998;65(4):494-9.

Saito T, Shinzawa H, Uchida T, et al. Quantitative DNA analysis of low-level hepatitis B viremia in two patients with serologically negative chronic hepatitis B. J Med Virol 1999;58(4):325-31.

Thiers V, Nakajima E, Kremsdorf D, et al. Transmission of hepatitis B from hepatitis-B-seronegative subjects. Lancet= 1988;2(8623):1273-6.

Coffin CS, Michalak TI. Persistence of infectious hepadnavirus in the offspring of woodchuck mothers recovered from viral hepatitis. J Clin Invest 104(2):203-12.

Shiota G, Oyama K, Udagawa A, et al. Occult hepatitis B virus infection in HBs antigen-negative hepatocellular carcinoma in a Japanese population: involvement of HBx and p53. J Med Virol 2000;62(2):151-8.

Fabris P, Brown D, Tositti G, et al. Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C. J Clin Virol 2004;29(3):160-6.

Yuen MF, Ka-Ho Wong D, Lee CK, et al. Transmissibility of Hepatitis B Virus (HBV) Infection through Blood Transfusion from Blood Donors with Occult HBV Infection. Clin Infect Dis 2011;52(5):624-32.

Hui CK, Yu J, Au WY, et al. Sexual transmission of hepatitis B infection despite the presence of hepatitis B virus immunity in recipients of allogeneic bone marrow transplantation. J Clin Virol 2005;32(2):173-8.

Koike K, Kobayashi M, Gondo M, et al. Hepatitis B virusDNA is frequently found in liver biopsy samples from hepatitis C virus-infected chronic hepatitis patients. J Med Virol 1998;54(4):249-55.

Alavian SM, Carman WF, Jazayeri SM. HBsAg variants: Diagnostic-escape and diagnostic dilemma. J Clin Virol 2013;57(3):201-8.

Coleman PF, Chen YC, Mushahwar IK. Immunoassay detection of hepatitis B surface antigen mutants. J Med Virol 1999;59(1):19-24.

Ijaz S, Torre F, Tedder RS, et al. Novel immunoassay for the detection of hepatitis B surface 'escape' mutants and its application in liver transplant recipients. J Med Virol 2001;63(3):210-16.

Moerman B, Moons V, Sommer H, et al. Evaluation ofsensitivity for wild type and mutant forms of hepatitis B surface antigen by four commercial HBsAg assays. Clin Lab 2004;50(3-4):159-62.

Zaaijer HL, Vrielink H, Koot M. Early detection of hepatitis B surface antigen and detection of HBsAg mutants: a comparison of five assays. Vox Sang 2001;81(4):219-21.

Jeantet D, Chemin I, Mandrand B, et al. Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays. J Med Virol 2004;73(4):508-15.

Hollinger FB, Sood G. Occult hepatitis B virus infection: a covert operation. J Viral Hepat 2010;17(1):1-15.

Carman WF, Boner W, Fattovich G, et al. Hepatitis B virus core protein mutations are concentrated in B cell epitopes in progressive disease and in T helper cell epitopes during clinical remission. J Infect Dis 1997;175(5):1093-100.

Hofer M, Joller-Jemelka HI, Grob PJ, et al. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis 1998;17(1):6-13.

Nunez M, Rios P, Perez-Olmeda M, et al. Lack of 'occult'mhepatitis B virus infection in HIV-infected patients. AIDS 2002;16(15):2099-101.

Rodriguez-Torres M, Gonzalez-Garcia J, Brau N, et al. Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection: clinically relevant or a diagnostic problem? J Med Virol 2007;79(6):694-700.

Shire NJ, Rouster SD, Rajicic N, et al. Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr 2004;36(3):869-75.

Jilg W, Sieger E, Zachoval R, et al. Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: high percentage of carriers of hepatitis B and C virus. J Hepatol 1995;23(1):14-20.

Brechot C, Jaffredo F, Lagorce D, et al. Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. J Hepatol 1998;29(2):173-83.

Carvalho-Filho RJ, de Lucca Schiavon L, Narciso-Schiavon JL, et al. Clinical and histological impact of previous hepatitis B virus infection in patients with chronic hepatitis C. Liver Int 2009;29(1):133-40.

El-Sherif A, Abou-Shady M, Abou-Zeid H, et al. Antibody to hepatitis B core antigen as a screening test for occult hepatitis B virus infection in Egyptian chronic hepatitis C patients. J Gastroenterol 2009;44(4):359-64.

Khan MH, Farrell GC, Byth K, et al. Which patients with hepatitis C develop liver complications? Hepatology 2000;31(2):513-20.

Weinberger KM, Bauer T, Bohm S, et al. High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum. J Gen Virol 2000;81(Pt 5):1165-74.

How to Cite
1.
Dindoost P, Chimeh N, Hollinger BF, Saberfar E, Norouzi M, Jazayeri SM. The Pigeonhole of Occult Hepatitis B. Acta Med Iran. 52(8):582-590.
Section
Articles